No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 7 contracts
Samples: Common Stock Purchase Agreement (MMTec, Inc.), Common Stock Purchase Agreement (MMTec, Inc.), Common Stock Purchase Agreement (Myomo, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2012 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 4 contracts
Samples: Common Stock Purchase Agreement (Sanwire Corp), Common Stock Purchase Agreement (Liquidmetal Technologies Inc), Common Stock Purchase Agreement
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2020 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 4 contracts
Samples: Common Stock Purchase Agreement (Evofem Biosciences, Inc.), Common Stock Purchase Agreement (Nikola Corp), Common Stock Purchase Agreement (Nikola Corp)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2011 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 4 contracts
Samples: Common Stock Purchase Agreement (American Petro-Hunter Inc), Common Stock Purchase Agreement (Globalstar, Inc.), Common Stock Purchase Agreement (Delcath Systems Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2013 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 3 contracts
Samples: Common Stock Purchase Agreement (Amyris, Inc.), Common Stock Purchase Agreement (Bioheart, Inc.), Common Stock Purchase Agreement (Bioheart, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2009 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 3 contracts
Samples: Common Stock Purchase Agreement (Microvision Inc), Common Stock Purchase Agreement (Omeros Corp), Common Stock Purchase Agreement (Oncothyreon Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries subsidiaries respective businesses since December 31, 2021 2001 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse EffectEffect on the Company.
Appears in 3 contracts
Samples: Common Stock Purchase Agreement (Aksys LTD), Common Stock Purchase Agreement (Aksys LTD), Common Stock Purchase Agreement (Aksys LTD)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed or incorporated by reference in the Commission DocumentsRegistration Statement and the Prospectus, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2020 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Super League Gaming, Inc.), Common Stock Purchase Agreement (Verb Technology Company, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2016 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Humanigen, Inc), Common Stock Purchase Agreement (Bio Key International Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries respective businesses since December 31, 2021 2010 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (DryShips Inc.), Common Stock Purchase Agreement (DryShips Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2023 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Ordinary Share Purchase Agreement (TNL Mediagene), Ordinary Share Purchase Agreement (Blue Ocean Acquisition Corp)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries subsidiaries respective businesses since December 31, 2021 2003 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse EffectEffect on the Company.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Emisphere Technologies Inc), Common Stock Purchase Agreement (Emisphere Technologies Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December July 31, 2021 2012 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Santo Mining Corp.), Common Stock Purchase Agreement (Santo Mining Corp.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2010 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Microvision Inc), Common Stock Purchase Agreement (Microvision Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries subsidiaries respective businesses since December 31, 2021 2003 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse EffectEffect on the Company.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Tegal Corp /De/), Common Stock Purchase Agreement (Tegal Corp /De/)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31October 28, 2021 2022 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Securities Purchase Agreement (SeaStar Medical Holding Corp)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries subsidiaries respective businesses since December 31, 2021 2000 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse EffectEffect on the Company.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Collagenex Pharmaceuticals Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2019 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (CV Sciences, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31June 30, 2021 2009 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (ARYx Therapeutics, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2017 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Nordic American Offshore Ltd.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December March 31, 2021 2012 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Tauriga Sciences, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2009 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect or an Omeros Material Adverse Effect.
Appears in 1 contract
Samples: Platform Development Funding Agreement (Omeros Corp)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31June 30, 2021 2011 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Santa Fe Gold CORP)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2018 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Hermitage Offshore Services Ltd.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a consolidated balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31January 19, 2021 2022 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Core Scientific, Inc./Tx)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31November 20, 2021 2014 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31August 26, 2021 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries Subsidiaries’ respective businesses since December 31, 2021 2022 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Signing Day Sports, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary of its subsidiaries (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries Subsidiaries’ respective businesses since December March 31, 2021 and 2022 or which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Eiger BioPharmaceuticals, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31November 19, 2021 2012 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December October 31, 2021 2011 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31September 30, 2021 2023 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Spectaire Holdings Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a the consolidated balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries Subsidiaries’ respective businesses since December March 31, 2021 2022 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Rigetti Computing, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31September 30, 2021 2010 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2014 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December March 31, 2021 2010 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries subsidiaries respective businesses since December 31, 2021 2002 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse EffectEffect on the Company.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Cellegy Pharmaceuticals Inc)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries respective businesses since December January 31, 2021 2013 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission DocumentsDocuments or Commission Filings, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries subsidiaries' respective businesses since December 31, 2021 1999 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Genelabs Technologies Inc /Ca)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31January 13, 2021 2022 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Ordinary Shares Purchase Agreement (Tritium DCFC LTD)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31, 2021 2022, and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Inspire Veterinary Partners, Inc.)
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31September 30, 2021 2019, and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s 's or its Subsidiaries respective businesses since December 31, 2021 2016 and which, individually or in the aggregate, do not or would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any Subsidiary (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses since December 31August 16, 2021 and which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Appears in 1 contract
